Envision Pharma announces acquisition of Alligent Biopharm Consulting

Envision Pharma has announced the acquisition of Alligent Biopharm Consulting for an undisclosed fee.

The technology-enabled scientific communications company has purchase Alligent, a leading medical affairs agency, in order to expand the scope and variety of services it is able to offer in this field.

Alligent is known for developing and delivering strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. Its core skillsets include medical strategy development and planning, allied programme implementation and stakeholder support.

The acquired company's two principals, Joe Kohles and David Thompson, will be joining the Envision Pharma leadership team following the finalisation of the merger.

Envision's chief executive officer Brian Hepburn said: "By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigour."

The deal was supported by the Halifax Group, a leading private equity firm which invests in health and biopharma services businesses.